<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04232215</url>
  </required_header>
  <id_info>
    <org_study_id>19-004708</org_study_id>
    <nct_id>NCT04232215</nct_id>
  </id_info>
  <brief_title>Medical Grade, Smartphone-based, Fetal Heart Rate Monitor for Outpatient Use</brief_title>
  <official_title>Feasibility and Acceptability of a Medical Grade, Smartphone-based, Fetal Heart Rate Monitor for Outpatient Use: the HeraBEAT™ Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are assessing the ease of use and accuracy of the HeraBEAT™ device, a new device&#xD;
      used with a smartphone to monitor fetal heart rate during pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HeraBEAT™ is a wireless Smart Fetal Ultrasound Doppler measuring device designed to be&#xD;
      self-administered by the expectant mother throughout the different stages of pregnancy. The&#xD;
      HeraBEAT™ device safety and performance claims allow continuous and accurate measurement of&#xD;
      fetal heart rate (FHR) and maternal heart rate (MHR) throughout the pregnancy starting at 12&#xD;
      weeks gestation.&#xD;
&#xD;
      Technologically, HeraBEAT™ is similar to other FHR devices currently on the market in terms&#xD;
      of device usage but differ by design in its interface. The HeraBEAT™ device uses a&#xD;
      smartphone-based interface, with real time instructions for expectant mothers for determining&#xD;
      both MHR and FHR.&#xD;
&#xD;
      This study will recruit low risk expectant mothers from the Obstetrics and Gynecology&#xD;
      Department at Mayo Clinic Rochester. This is a mixed method; single center randomized&#xD;
      controlled trial comparing HeraBEAT™ to a standard home fetal Doppler monitor, in the&#xD;
      outpatient setting at a single academic institution, in the mid-west United States. The&#xD;
      overall study will be guided by an assessment of device functionality and user acceptability,&#xD;
      as well as an evaluation of the impact of the device on expectant mother's perception of&#xD;
      fetal well-being, as measured by standardized surveys.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>After approximately 8 weeks of monitoring, patients will complete an ease of use survey, then crossover to the alternate study product.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device ease of use</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measured using the self-reported System Usability Scale (SUS) on a scale from 1 to 5 (1 = strongly disagree and 5= strongly agree)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fetal Heart Rate detection</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of subjects to detect a fetal heart rate accurately using the device (less than 110 or greater than 160 bpm)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pregnancy Related</condition>
  <arm_group>
    <arm_group_label>HeraBEAT™ Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will monitor their fetal heart beat once weekly using the HeraBEAT™ device. After approximately 8 weeks of monitoring subjects will crossover to using the doppler fetal heart rate monitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Fetal Doppler Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will monitor their fetal heart beat once weekly using the doppler fetal heart rate monitor. After approximately 8 weeks of monitoring subjects will crossover to using the HeraBEAT™ device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HeraBEAT™</intervention_name>
    <description>A wireless Smart Fetal Ultrasound Doppler measuring device designed to be self-administered by the expectant mother throughout the different stages of pregnancy</description>
    <arm_group_label>HeraBEAT™ Intervention Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Doppler fetal heart rate monitor</intervention_name>
    <description>A hand-held ultrasound transducer that uses the Doppler Effect to provide an audible simulation of the heart beat and displays the number of beats per minute.</description>
    <arm_group_label>Standard Fetal Doppler Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Able to speak, read and understand English&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Owns a suitable iOS or Android device and demonstrates average control and basic&#xD;
             understanding of using a smartphone&#xD;
&#xD;
          -  At least 12 weeks gestation&#xD;
&#xD;
          -  Pregnancy documented as low risk&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any observed anomalies on first trimester dating or formal ultrasound&#xD;
&#xD;
          -  Multifetal gestation&#xD;
&#xD;
          -  Maternal history of defibrillation&#xD;
&#xD;
          -  Maternal history of electro-surgery&#xD;
&#xD;
          -  Patients with external electrical stimulators, cardiac pacemakers or requiring use of&#xD;
             MRI or other high frequency medical equipment&#xD;
&#xD;
          -  Clinical judgment that determines that the pregnancy is at high risk for complications&#xD;
&#xD;
          -  Any of the following high risk factors would disqualify the mother for the study:&#xD;
&#xD;
               -  Abnormal fetal anatomy&#xD;
&#xD;
               -  Chronic hypertension, including severe hypertension (&gt;160/110)&#xD;
&#xD;
               -  Possible ectopic pregnancy or pregnancy of unknown location&#xD;
&#xD;
               -  Multi-fetal pregnancy&#xD;
&#xD;
               -  Hypertensive disorders (chronic hypertension, gestational diabetes, preeclampsia)&#xD;
&#xD;
               -  Prior Pulmonary Embolism / Deep Vein Thrombosis / stroke&#xD;
&#xD;
               -  Anticoagulation during prior pregnancy (e.g. antiphospholipid antibody syndrome)&#xD;
&#xD;
               -  Prosthetic heart valve (non-bio)&#xD;
&#xD;
               -  Pulmonary hypertension&#xD;
&#xD;
               -  Mothers currently taking Immunosuppressants, Prednisone &gt; 10mg per day)&#xD;
&#xD;
               -  Women with mental health disorders (including eating disorders, severe&#xD;
                  depression, on antipsychotics)&#xD;
&#xD;
               -  Recurrent pregnancy loss (&gt;2 losses)&#xD;
&#xD;
               -  Current maternal malignancy&#xD;
&#xD;
               -  Prior myocardial infarction/cardiomyopathy&#xD;
&#xD;
               -  Bio-prosthetic heart valves&#xD;
&#xD;
               -  Marfan syndrome&#xD;
&#xD;
               -  Active liver disease (e.g. hepatitis)&#xD;
&#xD;
               -  Congenital heart disease&#xD;
&#xD;
               -  Coagulopathies including thrombophilias and bleeding disorders.&#xD;
&#xD;
               -  Pre-existing diabetes&#xD;
&#xD;
               -  Genetic disease/Cystic Fibrosis testing/anomalies in prior child&#xD;
&#xD;
               -  Incompetent cervix (prior cerclage)&#xD;
&#xD;
               -  Isoimmunization (Rh, Kell, etc.)&#xD;
&#xD;
               -  History of transplant or currently on Dialysis&#xD;
&#xD;
               -  Prior 2nd or 3rd trimester loss&#xD;
&#xD;
               -  Human Immunodeficiency Virus (HIV)&#xD;
&#xD;
               -  Inflammatory bowel disease&#xD;
&#xD;
               -  Asthma and currently on steroid to control disease&#xD;
&#xD;
               -  History of preterm delivery &lt;37 weeks&#xD;
&#xD;
               -  BMI &gt;40 (class 3 obesity)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvonne S Butler Tobah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maureen A Lemens, BSN</last_name>
    <phone>507-293-1487</phone>
    <email>lemens.maureen@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen A Lemens, BSN</last_name>
      <phone>507-293-1487</phone>
      <email>lemens.maureen@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laurie Mulhern</last_name>
      <phone>507-284-8160</phone>
      <email>mulhern.laurie@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Yvonne S. Butler Tobah, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

